 |
 |
Cancer Research Studies
Treatment: Lung Cancer
Treatment: Lung Cancer
Study Title:
MAGRIT 109493: A double-blind, randomized,
placebo-controlled Phase III study to assess the efficacy of recMAGE-A3
+ AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in
patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer
What is the purpose of this study?
The purpose of this study is to determine whether adding a vaccine
to boost immune response in conjunction with chemotherapy and surgery
will prove to be clinically effective (resulting in disease free survival)
in patients diagnosed with lung cancer.
Am I a candidate for this study?
- Do you have a stage IB through IIIA lung cancer that has been surgically removed?
- Can you perform most or all of your activities of daily living?
What do I have to do?
- Agree to have a sample of lung tissue tested for a particular protein. If your tissue is positive you may be eligible for the study.
- Agree to have blood drawn.
- Agree to undergo CT scan every 6 months, periodic chest x-rays, and physical exams.
- Receive a vaccine several times throughout the study.
- Agree to be contacted by the research staff for up to 5 years after beginning the study.
Why should I participate?
- Currently, chemotherapy is the standard treatment for stage II and III lung cancers.
- Many patients receiving chemotherapy will relapse.
- There is a medical need for additional treatments for stage IB to IIIA lung cancers.
- This vaccine has demonstrated effectiveness in earlier studies and may prolong disease free survival.
If you are interested in participating in this
lung cancer research study, please contact:
Kristin Sorensen, MS, RN, clinical research nurse
sorenk@holycrosshealth.org
301.754.7961
Principle Investigator: Kashif Firozvi, MD, medical
oncologist
Co-investigator: Lawrence Markovitz, MD thoracic surgeon
About Our Program
Prevention & Early Detection
Studies
Treatment Studies
Survivor Studies
Related Information